Pfizer collaborates with Acuitas, Beam Therapeutics

By The Science Advisory Board staff writers

January 11, 2022 -- Pfizer and Acuitas Therapeutics have entered into a development and option agreement under which Pfizer will have the option to license on a nonexclusive basis Acuitas' lipid nanoparticle (LNP) technology for up to 10 targets for vaccine or therapeutic development. Also, Pfizer and Beam Therapeutics entered into an exclusive four-year research collaboration focused on in vivo base-editing programs for three targets for rare genetic diseases of the liver, muscle, and central nervous system.

Acuitas Therapeutics is a private biotechnology company that develops delivery systems for nucleic acid therapeutics based on lipid nanoparticles. Acuitas' LNP technology is used in the Pfizer-BioNTech COVID-19 vaccine.

Financial details of the agreement were not disclosed.

The base-editing programs to be evaluated as part of the collaboration between Pfizer and Beam will leverage Beam's proprietary in vivo delivery technologies, which use mRNA and LNP to deliver base editors to target organs. The collaboration seeks to advance potentially transformative therapies for patients living with rare diseases, both firms said.

Beam will conduct all research activities, including candidate selection, for three undisclosed targets that are not included in Beam's existing programs. Pfizer may opt into exclusive worldwide licenses for each candidate, after which it will be responsible for all development activities, as well as potential regulatory approvals and commercialization for each candidate.

Beam will receive an upfront payment of $300 million and, assuming Pfizer exercises its opt-in license rights for all three targets, is eligible for development, regulatory, and commercial milestone payments for a potential total of up to $1.35 billion. Beam is also eligible to receive royalties on global net sales of each licensed program.


Copyright © 2022 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here